OTTAWA, Jan 17 (Reuters) - Canada's study into whether to approve Merck & Co Inc's COVID-19 oral antiviral treatment "is moving more slowly", federal Health Minister Jean-Yves Duclos said on Monday.
"There are some specific issues for this medication," Duclos told reporters after Ottawa approved an oral antiviral treatment by Pfizer Inc , but did not give details. In its pivotal clinical trial, Merck's pill had less impressive results than the one produced by Pfizer.
(Reporting by David Ljunggren)
((david.ljunggren@tr.com; +1 647 480 7891;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments